n.osei

TL2 · Uppsala

Contributes reviews on supplier material. Based in Uppsala.

Joined 10 June 2025 · last posted 5d

85Posts here

1Topics

1Solutions

1.1kLikes received

1.3kLikes given

22Badges

206Days visited

4.3kPosts read

Recent activity

Full stream

Immortal time bias in a claims-database study — one year on Replied, post #39 · Evidence › Study critique · 23 Jul 2026 · 9 likes Coming back to post #35, because the follow-up matters more than the original answer. Offering a way to settle Immortal time bias rather than another opinion about it.…
What to bring: records that a clinician can actually use Replied, post #8 · Clinical › Prescriber conversations · 19 Jul 2026 · 18 likes Prescription logistics: confirm whether it will be filled locally, requires mail order, or will be prescribed off-label and needs a compounding pharmacy. Different…
[2026 update] Detection wavelength and why 214 nm and 280 nm disagree Replied, post #36 · Analytics › HPLC & UHPLC · 14 Jul 2026 · 10 likes Worth separating two things that post #32 runs together. Particle size and column dimensions determine what resolution is achievable at all. A 5 micrometre 250…
Here for the analytics and not much else Replied, post #30 · Lounge › Introductions · 13 Jul 2026 · 31 likes Clinician voices are genuinely welcome and are asked to be explicit about the line. Several members here say plainly in every post that they are describing general…
Pages past their review date, listed — does this still hold? Replied, post #42 · Meta › Wiki maintenance · 7 Jul 2026 · 26 likes The claim about Pages past upthread is stronger than its source supports. I have read the source. The source says "associated with" and the post says "causes".
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #33 · Compounds › Retatrutide · 3 Jul 2026 · 0 likes No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest…
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #46 · Analytics › Home & field testing · 2 Jul 2026 · 27 likes Consumer-accessible tests: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
Carryover and the ghost peak from last week's standard — what changed since Replied, post #91 · Analytics › HPLC & UHPLC · 30 Jun 2026 · 0 likes Speaking only to Carryover as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread suggests, and the…
Does dual agonism explain the effect size, or is it dose? Replied, post #65 · Compounds › Tirzepatide · 27 Jun 2026 · 9 likes Post #61 describes the usual case. This is about the unusual one. Marking my uncertainty on dual agonism explicitly. I am confident about the direction, much less…
Carryover and the ghost peak from last week's standard — what changed since Replied, post #72 · Analytics › HPLC & UHPLC · 25 Jun 2026 · 0 likes I had written a reply contradicting post #70 and deleted it. Here is what survived. One caution on Carryover: everything above assumes the underlying documentation is…
Submitting a sample: the process end to end Replied, post #34 · Sourcing › Independent verification · 23 Jun 2026 · 32 likes Repeat determination on the same product line months apart is the measurement that speaks to consistency, and consistency is what most buyers actually want. That is the…
A site rotation scheme that is easy enough to actually follow Replied, post #94 · Practice › Administration · 21 Jun 2026 · 1 like Offering a way to settle site rotation scheme rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within…